FewerJobs.

Perspective Therapeutics Inc jobs

76 matches, filter-driven and evidence-linked.

Reset
24 shown of 76

Benefit evidence

Resolvable source Inferred from posting Unknown provenance
Only verified benefits
  • Associate Director, Alliance & Business Operations

    Summit Therapeutics - Palo Alto, California, United States
    Indexed from Greenhouse Comp disclosed in posting
    4 days ago

    Why we showed this

    Employer: semantic matchDescription: "inc"
    +3
    Unspecified Other - Director Plus From the posting source $169K-$198K From the posting source Equity

    Associate Director, Alliance & Business Operations Palo Alto, California, United States About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab

  • Commercial Director, Intercontinental, Rheumatology - MEAR, CAN

    AbbVie Inc. - Mettawa, IL, United States
    Indexed from Smartrecruiters Benefit evidence checked Nov 20, 2026
    posted 30 days ago

    Why we showed this

    Description: "perspective"Description: "inc"
    +3
    Unspecified Other - Director Plus From the posting source Salary not disclosed Equity Inferred from posting 401(k) reported

    Commercial Director, Intercontinental, Rheumatology - MEAR, CAN Mettawa, IL, United States Company Description: About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology and neuroscience - and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com . Follow @abbvie on LinkedIn, Facebook , Instagram , X and YouTube. Job Description: The Commercial Director, Intercontinental is a key member of the Intercontinental Commercial Area Team, reporting to the Intercontinental Commercial Lead. This role will be responsible for supporting Therapeutic strategies across Intercontinental Markets including - Large Business Units: Puerto Rico and Latin America, through partnering with commercial directors assigned to those markets. The role has the responsibility of being a subject matter expert of our Therapeutic Profile within the Intercontinental Area and will be assigned key responsibilities based on the area priorities to represent the therapeutic area within global teams or broader Area forums and projects. Key Responsibilities: Build a comprehensive understanding of assigned LBUs market dynamics, trends, insights. Map out all opportunities from business and financial perspective and deliver on cross functional priorities to support business growth across assigned LBUs. Develop clear understanding of Affiliate's needs and provide support to Affiliate Brand team strategy, operations, and execution/performance. Partner with NPI/commercial leads to develop an annual business plan

  • 2027 Future Talent Program - Device Development & Technology - Systems & Human Factors Engineering - Co-op

    Merck & Co., Inc. - USA - New Jersey - Rahway
    Indexed from Workday Benefit evidence checked Nov 20, 2026 Comp disclosed in posting
    3w ago

    Why we showed this

    Description: "perspective"Description: "inc"
    +4
    Unspecified Other - Mid From the posting source $40K-$111K From the posting source Equity Inferred from posting 401(k) reported

    2027 Future Talent Program - Device Development & Technology - Systems & Human Factors Engineering - Co-op USA - New Jersey - Rahway Job Description The Future Talent Program offers co-ops of up to 6-months, each involving one or more projects designed to support your professional growth. These opportunities in our Research & Development Division provide valuable development while allowing you to explore whether we are the right company for your long-term career goals. Our success depends on the integrity, knowledge, imagination, skill, diversity, and teamwork of people like you. That is why we strive to foster an environment of mutual respect, encouragement, and collaboration. As part of our global team, you will work alongside talented and dedicated colleagues while developing and expanding your career. Within our company, the Pharmaceutical Sciences & Device Development organization is responsible for translating therapeutic agents into functional drug products optimized for patients. The Device Development & Technology team focuses on discovering, developing, and commercializing superior delivery devices - including dry powder inhalers (DPI), metered dose inhalers (MDI), nasal and parenteral systems (ophthalmic, injectables, and implants) - to support small molecules, biologics, and vaccine therapeutics requiring complex delivery routes. We are seeking co-op candidates at all levels with strong academic performance, communication skills, teamwork, and the ability to work in a multi-functional environment. The co-op will participate in departmental and project team meetings, gaining a broad perspective on the drug development process in the pharmaceutical industry. In addition, the co-op will have the opportunity to

  • MSL Field Medical Director, Oncology - Northeast

    AbbVie Inc. - Remote | Detroit, MI, United States
    Indexed from Smartrecruiters Benefit evidence checked Nov 20, 2026
    posted 36 days ago

    Why we showed this

    Description: "perspective"Description: "inc"
    +3
    Remote From the posting source Healthcare From the posting source - Director Plus From the posting source Salary not disclosed Equity Inferred from posting 401(k) reported

    MSL Field Medical Director, Oncology - Northeast Remote | Detroit, MI, United States Company Description: About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology and neuroscience - and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com . Follow @abbvie on LinkedIn, Facebook , Instagram , X and YouTube. Job Description: The Field Medical Director is the regional Field Medical Leader responsible for leading, coaching, and developing Field Medical teams to deliver high-quality, compliant scientific engagement and identify impactful healthcare professional perspectives and Scientific Intelligence. The role translates medical and therapeutic area strategy into regional field execution, elevates the quality and consistency of scientific exchange, and ensures that field-captured insights inform medical planning and evidence strategy. Through strong people leadership and scientific stewardship, the Field Medical Director strengthens AbbVie's field medical impact across the region.​ Responsibilities: ​​Lead, coach, and develop Field Medical Team members to deliver consistent, high-quality, non-promotional scientific engagement for the multiple myeloma therapeutic area. ​Translate medical and therapeutic area strategy into clear regional field priorities and execution plans. ​Establish expectations and standards for scientific exchange, healthcare professional perspectives and Scientific Intelligence, and compliant field execution. ​Review, interpret, and elevate field-identified healthcare professional perspectives and Scientific Intelligence to inform medical planning and evidence needs.

  • Director, CMC Product Development - Late Stage, Operations

    AbbVie Inc. - North Chicago, IL, United States
    Indexed from Smartrecruiters Benefit evidence checked Nov 20, 2026
    2w ago

    Why we showed this

    Description: "perspective"Description: "therapeutics"
    +4
    Unspecified Other - Director Plus From the posting source Salary not disclosed Equity Inferred from posting 401(k) reported

    Director, CMC Product Development - Late Stage, Operations North Chicago, IL, United States Company Description: About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology and neuroscience - and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com . Follow @abbvie on LinkedIn, Facebook , Instagram , X and YouTube . Job Description: Purpose The Product Development Director (PDD) will be a member of the Operations Strategy & Pipeline Leadership (OSPL) team within the Product Development, Science & Technology (PDS&T) organization. Reporting to one of the Therapeutic Area Leads, the PDD will be responsible for pipeline programs from a Chemistry, Manufacturing, and Controls (CMC) perspective. They will lead the Product Presentation and Device Strategy Team (PPDST) and build the CMC development strategy for the late-stage assets, aligning with the clinical and regulatory development strategy from the Asset Strategy Team (AST). The programs can span modalities and presentations. Modalities can include small molecules, biologics (protein, gene therapy, toxin etc.) and antibody drug conjugates. Product presentations can include oral dose, parenteral and devices (therapeutics and aesthetic). The PDD is accountable for creating a CMC development plan in collaboration with line functions and ensures strategic alignment with the enterprise functions (Clinical, Regulatory and Commercial) cross-functionally at the AST. The PDD

  • Associate Director, Patient and Access Analytics

    Cytokinetics Inc - 2 Locations
    Indexed from Workday Benefit evidence checked Nov 20, 2026 Comp disclosed in posting
    1w ago

    Why we showed this

    Employer: semantic matchEmployer: "inc"
    +2
    Unspecified Data From the posting source - Director Plus From the posting source $198K-$231K From the posting source Equity Inferred from posting 401(k) reported

    Associate Director, Patient and Access Analytics 2 Locations Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. As a key member of the Business Insights and Analytics team within the commercial domain of Cytokinetics, you will provide measurement and analytics to a broad array of data sources (access, payer, patient services/hub, trade, specialty pharmacy) to drive business decision making across market access, patient experience & operations, and trade & distribution. Owning the payer, access, and patient experience analytics roadmap, you will partner directly with Value and Access, Patient Experience & Operations, Trade & Distribution, Field, and other cross functional leaders, with a clear line of sight from your measurement & analysis to business and patient impact. Your work will include building and owning measurement, performance, and analytics frameworks in the areas of payer, access, treatment experience, patient operations, and trade & distribution to drive in-line & pre-launch market and performance insights, delivering scalable, automated insights and analytics across multiple platforms, and collaborating with internal stakeholders to shape commercial and analytics strategy. This role blends business acumen, technical expertise, and the ability to communicate insights effectively with executive and other non-technical audiences. The ideal candidate has a strong background in payer and access, patient operations, analyzing market trends and competitive landscape, and partnering closely across the insights, data, and IT teams to uncover

  • Engineer, Sterile Drug Product

    Viking Therapeutics - Viking Therapeutics, Inc.
    Indexed from Paylocity
    4w ago

    Why we showed this

    Description: "therapeutics"Description: "inc"
    +4
    Unspecified Other - Mid From the posting source Salary not disclosed Equity

    Engineer, Sterile Drug Product Viking Therapeutics, Inc. The Engineer of Sterile Drug Product provides strategic leadership and technical oversight for sterile injecta

  • Senior Analyst (R&D Finance/Accounting)

    Summit Therapeutics - Palo Alto, CA (US)
    Indexed from Greenhouse Comp disclosed in posting
    posted 88 days ago

    Why we showed this

    Description: "inc"Employer: "therapeutics"
    +2
    Unspecified Finance From the posting source - Senior From the posting source $117K-$130K From the posting source Equity

    Senior Analyst (R&D Finance/Accounting) Palo Alto, CA (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab

  • Senior Clinical Trial Manager

    Viking Therapeutics - Viking Therapeutics, Inc.
    Indexed from Paylocity
    posted 91 days ago

    Why we showed this

    Description: "inc"Description: "therapeutics"
    +4
    Unspecified Healthcare From the posting source - Senior From the posting source Salary not disclosed Equity

    Senior Clinical Trial Manager Viking Therapeutics, Inc. The Senior Clinical Trial Manager will support the conduct of clinical trials and data collection and review,

  • Manager, FP&A

    Summit Therapeutics - Palo Alto, CA
    Indexed from Greenhouse Comp disclosed in posting
    posted 32 days ago

    Why we showed this

    Description: "inc"Employer: "therapeutics"
    +2
    Unspecified Finance From the posting source - Mid From the posting source $139K-$163K From the posting source Equity

    Manager, FP&A Palo Alto, CA About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational

  • Manager, GMP Quality Operations

    Viking Therapeutics - Viking Therapeutics, Inc
    Indexed from Paylocity
    posted 73 days ago

    Why we showed this

    Description: "therapeutics"Description: "inc"
    +4
    Unspecified Other - Mid From the posting source Salary not disclosed Equity

    Manager, GMP Quality Operations Viking Therapeutics, Inc The Manager, GMP Quality Operations is responsible for day-to-day Quality oversight of GMP manufacturing and t

  • Functional Genomics Senior Scientist/Assistant Director

    Ionis Pharmaceuticals - 2855 Gazelle Ct HQ USA; MA 1 Beacon-USA ION; Remote
    Indexed from Ukg Pro Benefit evidence checked Nov 20, 2026
    posted 116 days ago

    Why we showed this

    Description: "perspective"Apply link reachable when checked
    Remote From the posting source Data From the posting source - Director Plus From the posting source Salary not disclosed Equity Inferred from posting 401(k) reported

    Functional Genomics Senior Scientist/Assistant Director 2855 Gazelle Ct HQ USA; MA 1 Beacon-USA ION; Remote We are seeking an exceptional computational biologist to lead target identification and multi-omics research efforts. In this role, you will drive the use of high-throughput, transcriptomics, epigenomics, proteomics, and functional genomics data to identify and prioritize novel therapeutic targets. You will bring a strategic, industry-wide perspective on the field - staying ahead of where it is moving and translating that into a differentiated approach which will align with Ionis's RNA-targeting and oligonucleotide platforms. You will lead a team of computational biologists, shape analytical strategy, and partner tightly with biology, human genetics, and drug discovery colleagues to bring forward the next wave of therapeutic targets.

  • Senior Medical Science Liaison (IL, WI)

    Summit Therapeutics - Chicago, Illinois, United States
    Indexed from Greenhouse Comp disclosed in posting
    posted 44 days ago

    Why we showed this

    Description: "inc"Employer: "therapeutics"
    +2
    Unspecified Healthcare From the posting source - Senior From the posting source $200K-$235K From the posting source Equity

    Senior Medical Science Liaison (IL, WI) Chicago, Illinois, United States About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus

  • Senior Legal Counsel

    Summit Therapeutics - Princeton, NJ
    Indexed from Greenhouse Comp disclosed in posting
    posted 35 days ago

    Why we showed this

    Employer: "therapeutics"Location: "inc"
    +2
    Unspecified Legal From the posting source - Senior From the posting source $203K-$243K From the posting source Equity

    Senior Legal Counsel Princeton, NJ About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational

  • Medical Science Liaison, Obesity

    Viking Therapeutics - Viking Therapeutics, Inc.
    Indexed from Paylocity
    2w ago

    Why we showed this

    Description: "inc"Description: "therapeutics"
    +4
    Unspecified Healthcare From the posting source - Mid From the posting source Salary not disclosed Equity

    Medical Science Liaison, Obesity Viking Therapeutics, Inc. The Medical Science Liaison (MSL) will serve as a field-based scientific resource and trusted peer to the obes

  • Associate Director, Medical Writing

    Indexed from Greenhouse Comp disclosed in posting
    posted 43 days ago

    Why we showed this

    Description: "inc"Employer: "therapeutics"
    +2
    Remote From the posting source Healthcare From the posting source - Director Plus From the posting source $169K-$198K From the posting source Equity

    Associate Director, Medical Writing remote About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational

  • posted 109 days ago

    Why we showed this

    Description: "therapeutics"Description: "inc"
    +4
    Unspecified Healthcare From the posting source - Director Plus From the posting source Salary not disclosed Equity

    Associate Director, Medical Writing & Scientific Communications Viking Therapeutics, Inc. The Associate Director, Medical Writing & Scientific Communications will be a key member of the Medical Affair

  • Paralegal

    Summit Therapeutics - Palo Alto, CA (US)
    Indexed from Greenhouse Comp disclosed in posting
    posted 30 days ago

    Why we showed this

    Description: "inc"Employer: "therapeutics"
    +2
    Unspecified Legal From the posting source - Mid From the posting source $139K-$163K From the posting source Equity

    Paralegal Palo Alto, CA (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational

  • Quality Management Systems Manager (QMS Manager)

    Viking Therapeutics - Viking Therapeutics, Inc.
    Indexed from Paylocity
    1w ago

    Why we showed this

    Description: "inc"Description: "therapeutics"
    +4
    Unspecified Other - Mid From the posting source Salary not disclosed Equity

    Quality Management Systems Manager (QMS Manager) Viking Therapeutics, Inc. The Quality Management Systems Manager (QMS Manager), will work cross-functionally to drive and champion proje

  • Senior Medical Science Liaison (Location: Changsha)

    Biogen - Shanghai, China
    Indexed from Workday Benefit evidence checked Nov 20, 2026
    posted 33 days ago

    Why we showed this

    Description: "perspective"Apply link reachable when checked
    Unspecified Healthcare From the posting source - Senior From the posting source Salary not disclosed Equity Inferred from posting 401(k) reported

    Senior Medical Science Liaison (Location: Changsha) Shanghai, China This critical role is Biogen field medical force, working as a scientific expert in close collaboration with HCPs externally and cross- function deparments internally. In the meanwhile, this position will have opportunities to work closely with National strategic team to contribute to the SMA and ALS product strategy development. To establish, develop and maintain medical scientific collaborative relationships with current and future therapeutic experts in spinal muscular atrophy (SMA), ALS and other NMD products in development. Facilitate medical and scientific information exchange with the medical community on spinal muscular atrophy (SMA), ALS and other NMD products. Generate systematically medical insights and provide key learnings to the regional Medical team on regular basis as appropriate. Provide inputs to the China National Brand strategy from regional perspective as the regional medical Lead Contribute to the implementation of SMA/ALS product China development plan Work with Experts to develop clinical therapeutic concepts that support the advancement of the medical science within Biogen´s scientific and therapeutic area of interest. Support the development and implementation of the internal training plan, monitor the plan and update knowledge of disease area. Deliver clinical and scientific presentations to regional healthcare audiences aligned with central medical education programs. Organize local/regional educational meetings with multidisciplinary participation of key stakeholders in designated area and provide key learnings to the Regional Medical team. Support therapeutic experts in developing concepts and protocols for SRAs / IITs / registries that support orphan drug therapies. Work with local

  • Associate Director, Pharmacovigilance Operations

    Indexed from Greenhouse Comp disclosed in posting
    3 days ago

    Why we showed this

    Description: "inc"Employer: "therapeutics"
    +2
    Remote From the posting source Other - Director Plus From the posting source $160K-$240K From the posting source Equity Unknown provenance 401(k) reported

    Associate Director, Pharmacovigilance Operations Remote Definium Therapeutics is a late-stage clinical biopharmaceutical company and our mission is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Our lead product candidate, lysergide tartrate (our proprietary orally disintegrating tablet form of lysergide (LSD) D-tartrate), represents a highly differentiated, potential best-in-class opportunity for patients suffering from generalized anxiety, major depressive disorder, and posttraumatic stress disorder. Our early stage pipeline includes DT402, the R-enantiomer of MDMA and is under development to target the core symptoms of autism spectrum disorder (ASD), specifically addressing social communication challenges. Guided by the recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address the underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today's mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX. Together we are moving psychiatry forward-beyond better, into a boundless future. Join us! Definium Therapeutics, Inc. is seeking a Associate Director, Pharmacovigilance Operations to play a key role in setting and executing on departmental strategy, as well as managing the day-to-day functioning of the Pharmacovigilance department. The incumbent will be responsible for overseeing departmental activities associated with investigational products. This role provides an outstanding opportunity to work in a matrix environment and collaborate with colleagues from Biometrics, Clinical

  • VP, DM1 Commercial Asset Lead

    DYNE Therapeutics - Waltham, MA
    Indexed from Greenhouse Benefit evidence checked Nov 20, 2026 Comp disclosed in posting
    posted 156 days ago

    Why we showed this

    Description: "inc"Description: "therapeutics"
    +3
    Unspecified Other - Director Plus From the posting source $272K-$340K From the posting source Equity Inferred from posting 401(k) reported

    VP, DM1 Commercial Asset Lead Waltham, MA Company Overview: Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/ , and follow us on X , LinkedIn and Facebook . Role Summary: The VP, DM1 Commercial Asset Lead (CAL) is a passionate driver of the value of Dyne's DM1 commercial asset with a global perspective, bringing adaptable leadership to develop and implement commercialization strategies that maximize reach and value creation within the neuromuscular portfolio. This mandate includes market analysis, competitive positioning, launch readiness and execution, and input into lifecycle management to support long-term success in bringing the asset to patients globally. The CAL is a highly visible leadership role and, as a key member of the Program Team, works cross-functionally to influence and help shape Program strategy. The CAL leads the definition of commercialization strategy, strategic imperatives, critical success factors, executional priorities, and global launch planning in close partnership with affiliate launch teams. This role balances a forward-looking orientation toward broad global access for patients with a pragmatic approach to planning,

  • Senior Medical Science Liaison (Mountain West)

    Summit Therapeutics - Remote (US)
    Indexed from Greenhouse Comp disclosed in posting
    posted 86 days ago

    Why we showed this

    Description: "inc"Employer: "therapeutics"
    +2
    Remote From the posting source Healthcare From the posting source - Senior From the posting source $200K-$235K From the posting source Equity

    Senior Medical Science Liaison (Mountain West) Remote (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab

  • Associate Scientist, Bioanalytical Assays

    Serif Health - Cambridge, MA
    Indexed from Greenhouse Comp disclosed in posting
    3w ago

    Why we showed this

    Description: "inc"Description: "perspective"
    +2
    Unspecified Other - Mid From the posting source $96K-$126K From the posting source

    Associate Scientist, Bioanalytical Assays Cambridge, MA Company Summary: Serif Biomedicines is a privately held, early-stage biotechnology company developing a novel approach to gene therapy that can address currently untreatable diseases. Serif Biomedicines was founded by Flagship Pioneering, an innovation enterprise that conceives, creates, resources, and grows first-in-category life sciences companies. Flagship Pioneering has created over 100 groundbreaking companies over the past twenty years, all of which are pioneering novel and proprietary biological, industrial, and engineering approaches to solve major needs in human health and sustainability. These companies include Moderna (MRNA), Syros Pharmaceuticals (SYRS), Seres Therapeutics (NASDAQ:MCRB), Generate Biomedicines, Tessera Tx, Evelo Biosciences (EVLO), and Indigo Agriculture. Position Summary: We are searching for an experienced Associate Scientist to drive bio-analytical assays for a novel DNA platform. More broadly, we are looking for an individual who enjoys working with in vitro and in vivo assays, and brings scientific rigor, intellectual curiosity, enthusiasm, and a desire to innovate new nucleic acid therapeutics. This individual will have the opportunity to work in a dynamic and fast-paced entrepreneurial environment, working both independently and as part of a highly collaborative and rapidly growing team. Key Responsibilities: Execution and analysis of bioassays, to assess efficacy, safety and biodistribution of novel nucleic acid therapeutics in rodents and NHPs Contribute to scientific and technical perspectives to advance platform development. Develop, optimize, and execute ligand binding assays to support studies in-house and at CROs. Effectively communicate experimental findings in oral, written, and visual formats. Work independently and collaboratively in a

Take this list with you

Download the 76 matching jobs in any format - read offline, archive, or hand to an AI assistant with your resume to find the best fits.

Or email it to me instead

The AI-ready prompt is a pre-written question you can paste into Claude, ChatGPT, Gemini, or Perplexity along with your resume. We never see your resume; this happens in your AI client of choice.

AI agent reading directly? Same data lives at /api/jobs.json?page=2&q=Perspective+Therapeutics+Inc&quality=all. See /llms.txt and /api/openapi.json for the full schema.